To the Editor: Adult-onset Still disease (AOSD) is an inflammatory disease characterized by fever, polyarthritis, and skin inflammation, with increased serum levels of interferon-(IFN-), interleukin 1 (IL-1), IL-18, IL-6, tumor necrosis factor-, IL-8, IL-2 receptor, C-X-C motif chemokine 10, and C-X-C motif chemokine 13 (CXCL13). 1 The cutaneous manifestations of AOSD include the classic evanescent skin eruption (ESE) and atypical persistent skin eruptions (APSEs), the latter possibly being related to more severe AOSD forms. 2 The aim of this study was to analyze the expression of key cytokines that are possibly involved in the skin inflammation of AOSD. A total of 13 patients with AOSD (according to the Yamaguchi and/or Fautrel criteria) with skin lesions (7 ESEs and 6 APSEs) and 9 healthy donors were included. Hematoxylin-eosinestained slides from all the patients were blindly examined by 2 pathologists (M.B. and M.D.V.P.). Total RNA was extracted from five 20-m-thick paraffin tissue sections. Quantitative polymerase chain reaction was performed with Applied Biosystems Power Sybr Green PCR Master Mix (Invitrogen, Carlsbad, CA).
APSEs manifested as linear urticaria (n ¼ 4), pigmented papules and plaques (n ¼ 1), and a dermatomyositis-like eruption (n ¼ 1). APSE histology showed a more abundant neutrophilic infiltrate and more frequent epidermal alterations.
Comparison between the skin of AOSD patients and that of healthy donors showed a significantly higher expression of IL-1 (P ¼ .04) and increased levels of expression of interferon-(IFN-) (P ¼ .06), IFN-(P ¼ .1), IL-6 (P ¼ .1), IL-8 (P ¼ .06), CD68 (P ¼ .1), and MCP-1 (P ¼ .1) in the skin of patients with AOSD (Fig 1) . Unexpectedly, level of expression of IL-18 was significantly lower (P ¼ .01) in the skin of patients with AOSD than in skin from healthy donors. The skin of patients with APSEs showed significantly higher levels of expression of IFN-(P ¼ .04), IFN-(P ¼ .04), IFN-receptor (P ¼ .003), and CXCL13 (P ¼ .02) and increased levels of expression of IL-6 (P ¼ .09), IL-8 (P ¼ .06), and CD68 (P ¼ .05) than the skin of patients with ESEs (Fig 2) . Expression of IFN-was particularly high in the dermatomyositis-like skin eruption (78 times more expressed in dermatomyositis-like skin eruption than in healthy donor skin vs 15 times more expressed in all 6 APSEs than in healthy donor skin).
In this work, IL-1 and IL-6 were up-regulated in the skin of patients with AOSD, confirming the interest in targeting these cytokines for treatment of AOSD. 3 We found increased expression of IFN-in AOSD lesions, confirming a type 1 helper T-cell (Th1) polarization. Several cases of APSEs have been reported in AOSD; they were characterized by fixed urticaria and pigmented papules or plaques. APSE histology differs from ESE histology by virtue of a more abundant dermal neutrophil infiltrate and possible epidermal alterations. APSE was associated with higher treatment resistance. 2 We found increased expression of IL-6 proinflammatory cytokine, macrophage/neutrophil markers (IL-8 and CD68), IFN-and its receptor, and CXCL13 chemokine in APSEs compared with that in ESEs. Moreover, we found significantly increased expression of IFN-in APSEs compared with that in ESEs. IFN-is overexpressed in some autoimmune diseases, including systemic lupus erythematosus and dermatomyositis. 4 A subgroup of APSEs are characterized by a photodistributed erythema of the upper eyelids and Gottron papules that are very close to those of the dermatomyositis eruption. 5 APSEs may be the result of increased inflammatory stimuli involving different proinflammatory pathways, including an autoimmune pathway (Th1 and IFN-profile) and an autoinflammatory pathway (neutrophilic infiltrate). Neutrophils might also produce excessive neutrophil extracellular traps in APSE, as has already been described in lupus, which is a Th1-mediated disease. 
Tracking tumor kinetics in patients with germline CYLD mutations
To the Editor: Objective data on the rate of growth of skin tumors in the rare orphan disease CYLD cutaneous syndrome (CCS; synonym BrookeSpiegler syndrome) are lacking. Its clinical burden on patients is significant, warranting the clinical trial of personalized treatments. To inform the design of trials of novel therapies, natural history studies that capture the rate of tumor growth in CCS are needed. The absence of such data on this rare genetic disease prompted our work to gather opportunistic tumor measurements from radiologic investigations carried out in patients with CCS as part of their routine clinical care.
Here we report the rate of tumor growth in 3 patients with CCS who underwent serial computed tomography (CT) imaging for monitoring pulmonary cylindromas 1,2 or malignant tumors. Four individuals were identified as having undergone CT imaging following a retrospective case note and radiologic data review of 16 CCS patients attending a tertiary dermatogenetics center, 3 of whom had CT-detectable tumors.
3,4 These 3 females had been documented to carry a familial heterozygous mutation in the CYLD gene (c.2460delC). 5 They had features of a severe phenotype, including a history of complete scalp excision in 2 of them. Ethical approval to study these patients (who had given consent) was obtained from a research ethics committee.
In each patient, tumors were located and numbered on a baseline high-resolution CT scan. Each tumor was measured on every slice on which it was visible, after which the longest diameter measured was chosen for each time point. This axis of measurement was maintained on subsequent imaging. We elected to exclude tumors smaller than 3 mm, lesions seen on only 1 slice, confluent tumors, and tumors arising in scar tissue (as this tissue was often isodense to the tumor) to allow for maximal accuracy and reproducibility across all scans. Data from new lesions detected during interval scans were included from the point of first appearance and tracked in subsequent scans. Excised lesions for which more than 1 time point was measured were tracked to the point immediately before excision; tumors that were seen at only 1 measurement time point were excluded, as they did not contribute to the rate of change data. Relative changes in size were calculated by comparing measurements at the indicated time points against baseline. Patients were followed over a mean period of 495.6 days (range, 226-891 days).
Of the cutaneous cylindromas, 30 grew and 2 decreased in size during the period of observation. The mean size at baseline was 12.6 mm (range, 6.7-23.5 mm) (Fig 1, A) . The average increase in size of cutaneous tumors was 12.6% (range, e8.7% to 41.1%) per year (Fig 1, B) . Fourteen pulmonary cylindromas were studied; all of them increased in size. The mean size of the pulmonary tumors at baseline was 18.7 mm (range, 4.4-42.7 mm) (Fig 1, A) . The average increase in size of the pulmonary tumors was 16.3% (range, 1.1%-38.0%) per year (Fig 1, B) .
Our findings are important for the following reasons. First, these data may inform routine clinical surveillance intervals, with insights into both cutaneous and pulmonary tumor kinetics. Second, our approach is informative as a proof of principle that serial radiologic imaging can be used to monitor change in the size of cutaneous tumors in this 
